Figure 2.
Cumulative incidence of intravenous bisphosphonate initiation by presence or absence of appropriately timed multiple myeloma therapy (within 30 d of multiple myeloma diagnosis) among patients with multiple myeloma in the United States
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.